Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting.

25 Oct 2010

SCT transplantation benefits in Hodgkin's lymphoma is unclear

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation (SCT) with an unrelated donor. This is due to the fact that studies are lacking that compare this therapy with autologous transplantation or conventional chemotherapy without SCT.

30 Sep 2010

G-CSF compound may activate virus, increases risk of infection: Research

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

22 Sep 2010

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium S.p.A. today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.

14 Sep 2010

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, commented today on the ruling this week of a U.S. District Court blocking the federal government from funding research involving human embryonic stem cells. In issuing a preliminary injunction, the judge said it violated a law first passed in 1996 prohibiting federal money for research where a human embryo is destroyed.

25 Aug 2010

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

24 Aug 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Australian regenerative medicine company, Mesoblast Limited, today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration to discuss a proposed Phase 3 clinical trial program.

12 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.

18 Jun 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Osiris Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

SCT transplantation benefits in Hodgkin's lymphoma is unclear

G-CSF compound may activate virus, increases risk of infection: Research

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Soligenix first-quarter revenues decrease to $336,000

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

RayBiotech announces biomarker grant winners

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in